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Abstract Proarrhythmia, the development of new or worse arrhythmias in response
to drug therapy, is a major limitation to the development and use of new
drugs. There are different types of drug-induced proarrhythmia, including
long-QT syndrome (LQTS), short-QT syndrome and proarrhythmia related
to Na+-channel blockade/conduction impairment. By far the most important
form of proarrhythmia at present is drug-induced LQTS and its associated
characteristic tachyarrhythmia, torsades de pointes (TdP). TdP arises when
cellular action potentials (APs) are excessively prolonged, leading to arrhyth-
mogenic afterdepolarizations, especially early afterdepolarizations (EADs),
which trigger complex re-entry in a substrate involving increased transmural
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dispersion of repolarization. In vitro screening, increasingly involving high-
throughput assays, is used to assess potential candidate molecules and elim-
inate potentially problematic structures at an early stage of development. The
most commonly used screening assays assess drug block of the K+ current
carried by human ether-à-go-go (hERG) subunits, corresponding to the rapid
delayed-rectifier K+ channel, the overwhelmingly most common target of
TdP-inducing drugs. In addition, the effects of drugs on AP duration or the in
vivo equivalent, QT interval, are often assessed in animal models. Methods
available for repolarization-related proarrhythmic risk assessment include in
vitro (Langendorff-perfused rabbit or guinea pig hearts) and in vivo models
(such as a-adrenoceptor-stimulated rabbits, rabbits with reduced repolar-
ization reserve due to block of slow delayed-rectifier current, animals with
chronic atrioventricular block or animals with cardiac remodelling caused by
congestive heart failure). In silico modelling may be helpful for molecular
design of non-hERG blocking candidates and for optimization of compound
selection (at the molecular and pharmacological profile levels). Finally, clin-
ical evaluation of effects on electrocardiographic intervals (particularly QT)
and cardiac rhythm are often needed, both prior to drug approval and after
successful introduction on the market (postmarketing surveillance). The
successful avoidance of proarrhythmic complications is a shared responsi-
bility of the innovative pharmaceutical industry, regulatory authorities,
partners in the clinical drug development phase and practicing physicians.
This paper reviews the principal forms of proarrhythmia and the methods
that can be used to minimize the risk of proarrhythmia in drug development
and clinical practice, with particular emphasis on the most common and
problematic form, acquired LQTS.
For every year since 1900, except 1918,
cardiovascular diseases accounted for more
deaths than any other single cause of death in the
US.[1] Nearly 2400 Americans die of cardio-
vascular disease each day, an average of one
death every 37 seconds.[1] Estimates for the US
range from <200 000 to >450 000 sudden cardiac
deaths (SCDs) annually.[2] In most cases the
cause of SCD is ventricular tachyarrhythmia, in
particular ventricular fibrillation (VF).[2] In the
1970s, pharmaceutical companies developed a
great number of antiarrhythmic drugs, hoping to
be able to prevent cardiac arrhythmic episodes
and associated subsequent deaths. However, the
CAST (Cardiac Arrhythmia Suppression Trial)[3]
and SWORD (Survival With Oral d-Sotalol)[4]
studies provided evidence that Vaughan-Wil-
liams Class IC Na+-current (INa) blockers and
Class III rapid delayed-rectifier K+-current (IKr)
blockers both induce significant arrhythmia risk-
enhancement (albeit via different mechanisms).
These observations sensitized the medical com-
munity to the risks of ‘proarrhythmia’, defined as
the production of de novo arrhythmias or aggra-
vation of existing arrhythmias. Drug-induced
proarrhythmia episodes were first described in
patients receiving quinidine.[5,6] Later, proar-
rhythmia was established to be a problem with a
variety of non-cardiac drugs that can cause ar-
rhythmias as an idiosyncratic adverse reaction.[7]
A specific ECG pattern, with twisting points
and undulating peaks, often associated with
proarrhythmia by drugs that cause QT prolonga-
tion was recognized byDesertenne, who coined the
descriptive French term ‘torsades de pointes’
(TdP), meaning ‘twisting of the points’.[8] TdP has
a characteristic pathophysiology (figure 1a, dis-
cussed in detail in section 1.1) and canmanifest as
acutely decreased pump function and haemody-
namic instability, leading to syncope (sometimes
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with seizure-like activity), or via transformation
to VF, causing SCD (figure 1b).
Although a variety of mechanisms can cause
proarrhythmia, the most significant in drug de-
velopment and clinical practice are those related
to abnormal repolarization, which is the focus of
this paper. The objectives of this review are to
summarize the presently available preclinical and
clinical models for assessing proarrhythmic risk,
and to provide information about how repolar-
ization-related proarrhythmia can be minimized
in clinical practice.
1. Proarrhythmia and Drug Development
Because of concern about proarrhythmic
risks, new chemical entities are generally screened
for biomarkers of proarrhythmia liability early
during drug discovery and development. Basic
pharmacological and toxicological studies may
detect proarrhythmia forms such as ventricular
premature beats (VPBs), ventricular salvoes or
conduction block. For instance, inward L-type
calcium current (ICaL) blockers evoke atrioven-
tricular (AV) block at higher concentrations.[9-11]
Catecholamines may induce VPBs and catecho-
laminergic polymorphic ventricular tachycardia
(CPVT). The AV-block dog model is a well
developed screen for drug-induced ventricular
ectopy associated with TdP.[12] Dose-related
proarrhythmia is much easier to detect than
proarrhythmia that is only manifest in patients
with idiosyncratic predisposition. Many drugs
associated with drug-induced TdP produce
proarrhythmia as a rare manifestation, with an
incidence <1 case in 2000.[13,14] Conventional pre-
clinical and clinical screening methods are not
powered to detect these relatively rare events.[15]
Electrocardiographic QT-interval prolonga-
tion (considered to be a TdP risk biomarker) and
TdP have been the single most common cause of
withdrawal of marketed drugs in the past dec-
ade.[16] Therefore, TdP liability testing has be-
come a key element of contemporary new drug
development, since many drugs (including cardio-
vascular drugs, antibacterials, antifungals, anti-
malaria drugs, antihistamines, psychotropic agents,
gastrointestinal prokinetics and nonadjuvant anti-
cancer agents[17]) and in some cases even their
metabolites may provoke TdP. An up-to-date list
can be found at www.torsades.org. Thus, the
proarrhythmic liability of any drug under devel-
opment must be assessed to minimize as much
as possible the potential risk that these drug-
induced life-threatening arrhythmias will occur
during pharmacotherapy.[18] Safety pharmacol-
ogy testing of new drugs is a great financial and
practical burden for the pharmaceutical industry;
however, it is crucial in preventing the much
greater cost of developing an agent that will risk
human health and eventually have to be with-
drawn for safety reasons. The International
Conference on Harmonization (ICH) adopted a
preclinical (ICH S7B) and clinical (ICH E14)







































Fig. 1. Mechanisms and ECG appearance of torsades de pointes
(TdP). (a) Mechanism of TdP arrhythmia. (b) TdP in an a1-adreno-
ceptor-stimulated anaesthetized rabbit. ECG and arterial blood
pressure (BP) before and during arrhythmia. Arrows indicate ectopic
beats before TdP. EAD =early afterdepolarization; VPB = ventricular
premature beat; › indicates increase; fl indicates decrease.
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testing of new drugs for proarrhythmic, torsado-
genic effect.[19,20] Shortly afterwards, the US
FDA, European Union and Health Canada
adopted these guidelines.
1.1 Long QT Syndrome (LQTS) and the
Mechanism of Torsades de Pointes (TdP)
At about the time when quinidine-induced
TdP proarrhythmia was first described, it was
recognized that TdP can also be caused by inher-
ited arrhythmia syndromes,[21-23] subsequently
shown to be most commonly caused by genetic
channelopathies. It was also recognized that TdP
is associated with QT prolongation in ‘long QT
syndromes’ (LQTSs), congenital or acquired. A
variety of mutations/genetic syndromes (desig-
nated ‘LQT1-12’) and drugs cause abnormal
function of ion channels, leading to decreased
repolarizing currents (principally the rapid [IKr]
or the slow [IKs] component of the delayed recti-
fier potassium current) or to increased depolar-
izing currents (particularly the late sodium
inward current [INa] and L-type calcium current
[ICaL]) during the action potential (AP) pla-
teau.[24] The vast majority of drugs associated
with TdP selectively reduce IKr because of the
unique molecular structure of the underlying
channel (human ether-à-go-go [hERG] channel),
which has a long external vestibule that promotes
drug trapping.[13,24]
The clinical recognition of TdP is sometimes
difficult because the distinction between various
ventricular tachyarrhythmias can be arbitrary,
and drug-induced TdP, polymorphic ventricular
tachycardia (VT) and VF may represent discrete
entities within a spectrum of drug-induced
proarrhythmia.[25]
A number of hypotheses have been proposed
to explain the generation of TdP, but the exact
underlying mechanisms remain incompletely un-
derstood. It is generally accepted that early
afterdepolarizations (EADs) are involved,[26] but
whether they only provide triggers for a poly-
morphic re-entrant tachyarrhythmia or whether
they maintain TdP by acting as drivers with vari-
able conduction patterns is uncertain. Figure 1a
illustrates the mechanism by which TdP arises.
In the most widely accepted theory, TdP requires
both initiating and maintaining mechanisms. The
initiating mechanism is most typically provided
by EADs. Any reduction in net repolarizing cur-
rents predisposes to EADs, which can lead to
ventricular extrasystoles that trigger re-entrant
tachyarrhythmias (initiating mechanism).[27] EADs
are generated in phase 2 or 3 of a prolonged AP
by depolarizing currents that can be carried by
ICaL and INa, but also inward Na
+/Ca2+ ex-
changer (NCX) current.[28] Ectopic beats also
precede EADs in canine TdP models.[29] There is
evidence that focal activity generated in Purkinje
tissue is the primary trigger for TdP initia-
tion.[30,31] A growing body of data also suggest
that Ca2+-handling abnormalities play an im-
portant role in torsadogenesis.[12,28,32-38]
The TdP-maintaining mechanism includes the
‘4 dimensions’ of dispersion of cardiac repolariza-
tion in space and time: (i) transmural dispersion of
repolarization (TDR);[39,40] (ii) apico-basal disper-
sion;[36,41] (iii) interventricular dispersion;[29,42-44]
and (iv) temporal dispersion.[45,46] Temporal disper-
sion includes instability that can be a consequence
of the above-mentioned initiating mechanisms.[47]
Dispersion leads to increased heterogeneity of
refractoriness, which sets the stage for re-entrant
arrhythmia generation and maintenance.[27] In a
recent study mimicking LQT7 (gain-of-function
ICaL abnormality) in canine isolated ventricular
wedge preparations, ventricular trans-septal dis-
persion predisposed to TdP.[48] TdP is frequently
preceded by a short-long-short cycle-length se-
quence in both congenital and acquired LQTS,
with the second (ectopic) beat causing a post-
extrasystolic pause.[44,49,50] The long cycle (post-
extrasystolic pause) favours the development of an
EAD-induced extrasystole of subendocardial focal
origin by increasing TDR, and promotes sub-
sequent re-entry.[51,52] The first ectopic complex
and the TdP-inducing ectopic beat are often multi-
focal but can also be unifocal.[53] The characteristic
twisting morphology is attributed to the transient
bifurcation of a predominantly single rotating
scroll into two simultaneous scroll waves involving
the right and left ventricles separately.[54] Atrial
tachyarrhythmias, ‘atrial torsades de pointes’, may
also develop in LQTS.[55-58]
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1.2 Predicting TdP
It has been estimated that 2–3% of all drug
prescriptions include medications with the po-
tential to induce LQTS.[59] Since most clinical
trials are underpowered to detect adverse effects
as rare as TdP, reliable surrogate parameters
(biomarkers) are needed to predict the proar-
rhythmic liability of drugs. Because of the lim-
itations of the corrected QT interval (QTc) as a
biomarker (see section 3), there is great interest in
developing biomarkers with greater predictive
value for drug-induced arrhythmias based on
clinically relevant and predictable in vitro and
in vivo proarrhythmia models.[15,18,36,60-63] The
variables that have been suggested to be of po-
tential value in predicting proarrhythmic liability
are summarized in table I.
1.3 Other Types of Proarrhythmia
Table II summarizes the main characteristics
of congenital and corresponding drug-induced
forms of proarrhythmia. Theoretically, drugs
could cause proarrhythmia by mimicking effects
of any of the channelopathies that cause con-
genital arrhythmia syndromes. Although drug-
induced proarrhythmia has been produced in
experimental models of virtually all congenital
forms listed in table II, clinical counterparts have
only been described for some.
Quinidine can produce proarrhythmic epi-
sodes with properties different from TdP, with
wide QRS and monomorphic VT.[16] Similarly,
other Na+-channel inhibitors such as Class IC
antiarrhythmics (flecainide, encainide, mor-
icizine, propafenone) can lead to VT, as well as to
atrial fibrillation conversion to a slower atrial
tachyarrhythmia with 1 : 1 ventricular conduc-
tion.[125] The CAST study showed that Class IC
antiarrhythmics increase mortality, largely be-
cause of proarrhythmic liability, in patients with
prior myocardial infarction.[3] Loss-of-function
mutations of INa produce VT/VF predisposition
in the Brugada syndrome. A single mutation in
the INa gene (SCN5A) shows a unique overlap of
LQT3, Brugada syndrome and progressive con-
duction defects.[126-128] Brugada syndrome mani-
festations can be precipitated by drug exposure in
predisposed patients, most typically because of
Na+-channel blockade.[116] Although, because of
space limitations, this article focuses on proar-
rhythmia related to abnormal repolarization, the
potential importance of other forms of proar-
rhythmia such as those caused by INa-blockers
needs recognition.
A complementary condition to LQTS was
suggested by the observation that SCD risk is
doubled in patients with QT intervals shorter
than 400ms.[129] Gussak et al.[130] first reported a
case of hereditary short QT interval with syn-
cope, atrial fibrillation and sudden death. Later,
short QT syndrome (SQTS) was characterized as
a new clinical entity that can be caused by a
variety of mutations (corresponding to specific
syndromes designated ‘SQT1-5’), all of which
lead to enhanced repolarization (either by in-
creasing repolarizing K+-currents or decreasing
depolarizing Ca2+-currents), resulting in shorter
AP duration (APD) and QT interval.[131-133] Re-
duced APD decreases refractory period and pro-
motes re-entry. There is also a corresponding
drug-induced proarrhythmia syndrome,[134] which
is much rarer than drug-induced LQTS. APD/
QT-shortening drugs such as hERG activators
(RPR260243, PD-118057, mallotoxin, NS1643)
and ATP-sensitive potassium channel activators
(levcromakalim, nicorandil) can reverse the
AP-prolonging effects of dofetilide,[135,136] but
also cause significant QT and JT shortening, in-
creased Tpeak-Tend (see section 2.2.3) and produce
profibrillatory effects in isolated hearts. A re-
cently marketed antiepileptic drug, rufinamide,
significantly shortened the QT interval during
preclinical studies and was labelled with a con-
traindication in patients with familial SQTS and
caution in patients receiving other QT-shortening
drugs.[134]
Preclinical profiling should be extended to
predict these forms of proarrhythmic liability if a
signal of Na+-channel blocking or APD/QT
shortening risk is obtained. Because of the much
lower importance at present of proarrhythmia
syndromes other than acquired LQTS, we focus
primarily on the detection and prevention of ac-
quired LQTS risk in the rest of this paper.
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Table I. Potential electrophysiological and haemodynamic proarrhythmia parameters for acquired LQTS liability
Parameter Description Detection mode and comments References
preclinical clinical
Incidence of preceding ectopic beats
Ectopic beats Ventricular premature beats ECG, MAPD 44 64
R on T wave Ectopic beat falls within the T wave ECG 65,66 64
Repolarization morphology
TWA and mV-TWA Beat-to-beat alternation of the morphology,
amplitude and/or polarity of T wave
ECG 67-71
Tpeak-Tend Interval between the peak and the end of the
ECG T wave, provides an alternate ECG index
of TDR
Precordial ECG leads 39,72-74 75-77
Triangulation Prolongation of APD30 to APD90 APD 45
Beat-to-beat variability
TWLI Root-mean-square of the differences between
corresponding signal values of subsequent
beats
At least 100 T waves 78
Instability Difference between the upper quartile (the
upper boundary of the lowest 75% of the interval
values) and the lower quartile (the upper
boundary of the lowest 25% of the interval
values)
APD, ECG 35,45
STV Poincaré plot, the width of the plot, orthogonal to
the line-of-identity
MAPD, ECG (at least 30
consecutive beats)
46,79,80 81,82
LTV Poincaré plot, the length of the plot, parallel to
the line-of-identity
MAPD, ECG (at least 30
consecutive beats)
46
TI Poincaré plot, the median of the distances from
centre gravity
ECG (at least 30 consecutive
beats)
83
STI Poincaré plot, the width of the plot ECG (at least 30 consecutive
beats)
83
LTI Poincaré plot, the length of the plot, the distance
to the x coordinate
ECG (at least 30 consecutive
beats)
83
RMS Root mean square for a sequence of
consecutive ECG intervals
ECG 35
RMSSD Root mean square of successive differences of
consecutive ECG intervals
ECG 84 85





Percentage of successive RR/QT intervals that
differ by >50ms (human) or >8ms (rabbit)
ECG, RR interval (human)
ECG, QT interval (rabbit)
86 87
Heart rate-dependent repolarization parameters
QTc Heart rate corrected QT interval ECG 35,86 88
QTVI Log ratio between the QT interval and heart rate
variabilities, each normalized by the squared
mean of the respective time series
At least 256 sec ECG segment in
sinus rhythm
89,90






BRS Heart rate response to blood pressure changes,
indicator of parasympathetic nervous system
function
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2. Preclinical Models
A working set of recommendations was de-
veloped in the early 2000s, known as ICH S7B.
The goals of the document were to create a set of
standards for the identification of the con-
centration-related potential of drugs and their
metabolites to delay ventricular repolarization.
ICH S7B recommends at least a test of direct in-
hibition of IKr (e.g. hERG assay) and the appli-
cation of an in vivo model to assess ECG actions
and proarrhythmia. If the test substance belongs
to a chemical/pharmacological class with mem-
bers known to prolong QTc in humans, a test for
QT prolongation in humans should be per-
formed. The preclinical studies should provide an
overall estimate of QT-prolonging risk in humans
before the first administration to humans.[19]
Finally, an integrated risk assessment should be
performed, including the evaluation of preclinical
pharmacodynamic and pharmacokinetic data,
along with postmarketing surveillance and follow-
up studies relating to clinical QT prolongation.
It has become evident that no single model is
sufficient to detect TdP liability completely, and
even an integrated combination of approaches
cannot successfully estimate the proarrhythmic
liability of all drugs. It has therefore been
strongly suggested to construct the development
programme for each compound on a ‘case by
case’ basis.[137]
Because proarrhythmia liability assays aim for
clinical predictive value, the test model must be
relevant to human physiology, i.e. species with
radically different ionic-current repolarization
systems from man (e.g. rat, mouse) should be
avoided. The ICH S7B guidelines suggest per-
forming at least two preclinical models before
clinical administration.
Clinical TdP is relatively rare, but the in-
cidence of proarrhythmia and sensitivity for
proarrhythmic risk detection can be increased in
preclinical assays by incorporating risk contri-
butors that promote TdP. For example, slow
heart rates and reduced serum [K+] enhance TdP
likelihood, since lower cardiac frequencies ex-
aggerate APD prolongation due to hERG
blockers (reverse use-dependence) and increase
susceptibility to EADs, while decreased [K+] re-
duces IKr and background inward-rectifier (IK1)
conductance and enhances sensitivity to hERG
blockers.[16] Table III summarizes risk contri-
butors that are incorporated in preclinical assays
to enhance their sensitivity.
Table I. Contd
Parameter Description Detection mode and comments References
preclinical clinical
HRT Index of autonomic function defined by the
relationship between initial acceleration and
subsequent deceleration of sinus rhythm
following a ventricular ectopic beat
ECG, parasympathetic
(non-invasive), only in case
of extrasystoles
98-100
HRV Index of temporal heart rate variation ECG 101 102-104
SP SAP Frequency content analysis of temporal systolic
blood pressure trends, indicator of autonomic
tone




TRIaD Triangulation, reverse-use dependence,
instability and dispersion
MAPD 25,45
APD =action potential duration; BRS = baroreceptor sensitivity; HRT =heart rate turbulence; HRV =heart rate variability; LTI = long-term
instability; LTV = long-term variability; MAPD =monophasic action potential duration; pNN50 and pNN8 = the percentage of successive RR
and QT intervals that differ by >50ms and >8ms, respectively; QTc =heart rate corrected QT interval; QTVI =QT variability index; RMS = root
mean square; RMSSD = root mean square of successive QT differences; SDSD = standard deviation of successive QT differences;
SP SAP = spectral power of systolic arterial blood pressure; STI = short-term instability; STV = short-term variability; TDR = transmural
dispersion of ventricular repolarization; TI= total instability; Tpeak-Tend = interval between the peak and the end of the ECG T wave;
TRIaD = triangulation, reverse use-dependence, instability and transmural dispersion; TWA =T-wave alternans (mV-TWA =microvolt level
TWA); TWLI =T wave lability index.
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It is important to validate the efficiency of
various models for proarrhythmic risk-profiling.
Sensitivity expresses how well a model recognizes
drugs that can be proarrhythmic in humans. A
highly sensitive model may effectively filter drugs
that can be clinically harmful, but it may also pro-
duce false-positive results that stop the develop-
ment of potentially useful proarrhythmia-free
agents. Thus, an additional important indicator
is the specificity, which is a measure of how often
drugs identified as potentially proarrhythmic
truly have proarrhythmic risk. A reliable pro-
arrhythmiamodel requires validation showing that
it has sufficient sensitivity and specificity for
proarrhythmia screening.
Most pharmaceutical companies conduct
cardiovascular safety studies (frontloading) be-
fore selection of candidate drugs for develop-
ment.[147] Surveyed pharmaceutical companies
reported the use of hERG assays, isolated organ
studies, APD measurements and in vivo QT in-
terval measurements in 100%, 48%, 62% and 83%
of drug development screening programmes, re-
spectively.[147] Regulatory guidelines do not yet
contain recommendations for testing liability to
drug-induced proarrhythmia forms other than
LQTS (e.g. drug-induced Brugada syndrome and
SQTS). Eventually, new assays and models will
need to be developed and standardized for these
paradigms. Table IV summarizes the advantages
and disadvantages of the available preclinical
models for TdP risk assessment.
2.1 In Silico Modelling
Several in silico techniques are in development
for use in drug discovery. In silico approaches
include ligand-based modelling, target-based
modelling (e.g. structural modelling of potential
interactions with hERG and other ion channels)
and electrophysiological modelling of single cells
or even whole hearts.[148-150] An in silico hERG
modelling study reported impressive prediction
of blocking effects for a test set of 28 compounds,
with a sensitivity, specificity and accuracy of
90%, 86% and 89%, respectively.[151] In addition,
in silico models of adverse reactions and under-
standing of receptor systems are valuable tools
for early compound profiling.[152] In silico anal-
ysis has provided insights into the impact of
serum ion-level changes during haemodialysis on
drug-induced APD prolongation with potential
Table II. Characteristics of channelopathies with corresponding drug-induced proarrhythmia
Current Syndrome Gene Protein Mutation function Drug induced APD Arrhythmia References




IKs› SQT2 KCNQ1 KvLQT1 Gain R-L3 Shortened AF, VT, VF 108,109
IKrfl LQT2 KCNH2 hERG Loss Dofetilide
E-4031
Lengthened TdP 110-112





Shortened AF, VT, VF 113-115




AF, VT, VF 116-118
INa› LQT3 SCN5A Nav1.5 Gain ATX II
Veratridine
Lengthened TdP 40,119,120
ICaLfl SQT4 CACNA1C Cav1.2 Loss Shortened AF, VT, VF 121,122
ICaL› LQT8 CACNA1C Cav1.2 Gain BAY K8644
FPL64176
Lengthened TdP 34,123,124
AF =atrial fibrillation; APD =action potential duration; hERG = human ether-à-go-go subunit; ICaL= L-type calcium current; IKr = rapid delayed-
rectifier potassium current; IKs = slow delayed-rectifier potassium current; INa = sodium current; LQT = long QT; SQT = short QT; TdP =
torsades de pointes; VF = ventricular fibrillation; VT = ventricular tachycardia; › indicates increased; fl indicates decreased.
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impact on arrhythmias.[153] In silico modelling
has also provided insights regarding the response
to flecainide and mexiletine administration in
congenital LQT3 and Brugada syndrome pa-
tients.[154] Despite the usefulness of in silico
modelling, a recently reported study indicated
that only 37% of the 54 companies surveyed are
using this method to predict ion channel/hERG
channel interactions.[147] The in silico screens will
clearly not eliminate the necessity for in vitro
and in vivo screening methods in the near future.
However, the rational application of in silico
methods during early discovery phases may
allow for more cost- and resource-efficient de-
sign of candidate drugs with improved safety
profiles.[151]
2.2 In Vitro Models
A variety of in vitro animal models are used to
assess potential cardiac electrophysiological and
proarrhythmic effects. Effects can be studied at
levels ranging from ionic currents through ar-
rhythmia development in systems varying from
single cell models to complex organ preparations.
Generally, tests in simpler systems are less ex-
pensive and provide larger throughput, and are
therefore useful for initial screening. More com-
plex procedures are eventually needed for com-
pounds that pass initial screening and are taken
to further stages of development, or compounds
with particularly important clinical potential se-
lected despite early positive signals.
Table III. Risk contributors that enhance sensitivity of preclinical assays
Assay Risk contributors References
APD Limited repolarization reserve (Purkinje fibre)










Drug-induced weakening of repolarization reserve
139-141
Langendorff heart (SCREENIT) Bradycardia
AV block + pace





Pacing algorithms (mimic SLS sequence)
35,142





AV block, canine Anaesthesia (halothane, isoflurane, pentobarbitone)
Hypertrophy
Electrical remodelling (decreased repolarization reserve)
Hypokalaemia
Pacing algorithms (mimic SLS sequence)
12,144
Failing rabbit heart Hypertrophy
Heart failure





APD =action potential duration assessment; AV =atrioventricular; SLS = short-long-short.
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Table IV. Advantages and disadvantages of long QT syndrome-liability screens and measurable proarrhythmia parameters
















expression affects applicability to
humans
Moderate specificity
Purkinje fibres may not respond to







Wedgea Simultaneous AP and ECG
Direct determination of TDR
(recordings from the three layers)
High sensitivity
High specificity
Can detect proarrhythmia related to

















































Drug action on a1-adrenoceptor
complicates analysis of results
Moderate sensitivity (requires large
amount of drug)
Less validated
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Potential disadvantages of in vitro models re-
late to the fact that they exclude the effects of
plasma protein binding, the effects of metabo-
lites, effects of chronic drug exposure, and neu-
ronal and hormonal influences. In vitro results
can also be strongly influenced by certain physi-
cochemical properties of test drugs (e.g. adsorp-
tion to glass or plastic surfaces, poor solubility),
leading to reduced effective drug concentrations
and decreasing sensitivity.
2.2.1 Human Ether-à-Go-Go (hERG) Subunit Assay
In virtually all cases of drug-induced TdP,
culprit drugs inhibit the current carried by hERG
(IhERG), the a-subunit underlying IKr.[155] There-
fore, screening with a hERG-blocking assay is
very useful for identifying drugs that are likely to
have proarrhythmic potential. However, drugs
might affect additional cardiac ion channels,
which can either diminish or enhance QT-
prolonging and proarrhythmic potential. There-
fore, additional assays on cells, tissues or organs
may provide valuable information about net ef-
fects on repolarization and TdP risk.
IhERG/IKr assays can be performed in freshly
isolated cardiac ventricular myocytes or cell lines
expressing hERG, with Chinese hamster ovary
and human embryonic kidney cells being com-
mon choices.[156,157] Blocking potency (IC50, i.e.
the concentration that produces 50% inhibition)
can be assessed by standard manual electro-
physiology, but is increasingly performed with
automated patch-clamp methods.[157] The cardio-
myocyte system is the ‘gold-standard’, with more
reliable and accurate results, but has low
throughput and requires highly qualified human
resources.[157] In contrast, automated patch-
clamp methods provide very high throughput
with less precise IC50 values. IC50 values for
IhERG block can be influenced by experimental
protocol (e.g. step vs ramp protocol) and tem-
perature,[158,159] extracellular K+ concentra-
tion,[160,161] pulse rate[162] and solubility. Despite
efforts to standardize hERG assays, there can be
great variations in IC50 for a given drug among
research labs.[61]
For drugs with multichannel blocking activity,
the inhibition of INa and/or ICaL may offset APD
prolonging and proarrhythmic effects of IhERG/IKr
block. The ICaL blocker verapamil (which has
never been reported to cause TdP and can be
therapeutic for long QT-related arrhythmias) in-
hibits IKr in the same concentration range as
quinidine and amiodarone.[163] The antianginal
agent ranolazine possesses multiple channel
blocking properties, including IKr inhibition, and
suppresses EADs and TDR in canine perfused
wedge preparations and in vivo models.[164,165]
Thus, in some cases, reliance on hERG assays
alone can lead to unnecessary rejection of po-
tentially valuable compounds.
For drugs with weak IKr-blocking ability,
safety margins should be considered, taking into
account the IC50 and therapeutic free-drug plas-
ma concentration.[61] A hERG-blocking IC50
30-fold greater than the half-maximally effective
Table IV. Contd
Assay Advantages Disadvantages Proarrhythmia parameters
Conscious telemetryb Similar electrophysiology to the
human
No drug interaction









a Not able to inform about the effects of plasma protein binding, the effects of metabolites, effects of chronic drug exposure, and neuronal and
hormonal influences.
b Able to provide PK/PD information (i.e. dose-proarrhythmia curve, drug metabolism, drug-interaction).
AP = action potential; APD =AP duration; BVR = beat-to-beat variability of repolarization; DAD = delayed afterdepolarization; EAD = early
afterdepolarization; hERG = human ether-à-go-go; ICF = isometric contractile force; IKs= slow delayed-rectifier potassium current; INa =
sodium current; MAPD =monophasic action potential duration; PD = pharmacodynamics; PK = pharmacokinetics; TdP = torsades de pointes;
TDR = transmural dispersion of repolarization; TpTe = interval between the peak and the end of the ECG T wave; VF = ventricular fibrillation;
VPB = ventricular premature beat; VT = ventricular tachycardia.
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unbound-drug concentration has been suggested
to represent an adequate ‘cardiac safety in-
dex’.[166] However, this rule is clearly not abso-
lute, since verapamil is safe clinically despite a
cardiac safety index of 1.7 (see above).[167] It has
also been suggested that a lower margin (10-fold)
may be acceptable for drugs developed for life-
threatening conditions.[167]
Several drugs may lengthen QT intervals
without directly blocking IhERG, by inhibiting
hERG trafficking to the plasma membrane.[168-170]
In such cases, hERG assays may provide false-
negative results. Recently, an antibody-based
chemiluminescent assay called HERG-Lite was
developed and validated to accurately predict
both channel blockers and trafficking inhibi-
tors in a rapid, high-throughput, cost-effective
manner.[171]
Rubidium efflux assay may provide high-
throughput screening at relatively low cost, and
yield quantitative information about hERG-
inhibiting potential, but rubidium may reduce
IhERG inactivation, which decreases the sensitiv-
ity of the assay for the test drug.[172,173] A new
thallium flux assay was recently validated as an
alternative method to profile large-volume com-
pound libraries for hERG channel blocking ac-
tivity.[174] Human embryonic stem cell-derived
cardiomyocyte assays are also presently under
development.[175]
IhERG assays are able to detect hERG-current
activators, and might therefore be useful in
screening for drugs inducing SQTS. A recent
study applied IhERG assays to screen 170 com-
pounds, showing high specificity (97%) and
moderate sensitivity (55%) for hERG activators
and moderate sensitivity (66%) and specificity
(59%) for hERG blockers, with APD response
assay as the ‘gold standard’.[176]
Several hERG drug-binding sites have been
identified, at which mutations (e.g. F656, Y652)
decrease drug access to hERG.[177-179] The use of
hERG isoforms carrying such mutations can in-
crease specificity at the cost of decreased sensi-
tivity. Up to 40–86% of new chemical entities
may inhibit hERG at high concentrations (i.e. up
to the limit of solubility).[180] Witchel[181] esti-
mated that 40–70% of new chemical entities have
to be abandoned because of an inadequate win-
dow for hERG blockade. Additional tests may be
required for compounds that pass hERG assay if
a preclinical signal for QT prolongation or
proarrhythmia is obtained, and some particularly
promising drugs in challenging therapeutic areas
may be subjected to further testing to assess
proarrhythmic potential more deeply despite a
positive signal on hERG assay.
2.2.2 Purkinje Fibre and Papillary Muscle Action
Potential Duration Assays
One limitation of the hERG assay is that it
predicts TdP risk for hERG-blocking drugs that
have low proarrhythmic liability by virtue of in-
ward current-blocking actions that antagonize
the consequences of IKr-block.
[182] APD assays
with fine-tipped microelectrodes in multicellular
preparations provide precise information about
drug-induced changes in the shape and duration
of APs at varying stimulation rates. Guinea pig,
rabbit or canine papillary muscle and Purkinje
fibre APD assays are used most commonly in
preclinical safety studies.[147] APD recordings are
easy to perform and plasma proteins can be
added to the system to control for protein bind-
ing effects.[183] Changes in AP shape are at least
as important as changes in APD. A recent study
showed that repolarization risk evaluation based
on APD90 values detected two of six clinically
positive compounds, whereas five of six com-
pounds were detected based on AP triangula-
tion.[184] Purkinje fibre APD assessment may be
superior for detecting proarrhythmic repolariza-
tion-delaying properties.[185] The QT PRODACT
project showed that guinea pig papillary muscle
APD assay predicts QT interval prolongation
in humans.[186] However, APD assay is not
predictive of all QT-prolonging drugs (e.g. terfe-
nadine),[187] does not reliably predict the torsa-
dogenic potential of all drugs and has moderate
throughput. APD assays, with their high sensi-
tivity and moderate specificity, may therefore be
of most value in clarifying incoherent results of
ion channel studies, assessing drugs with multiple
channel blocking ability or defining mechanisms
of actions.[147]
584 Farkas & Nattel
ª 2010 Adis Data Information BV. All rights reserved. Drugs 2010; 70 (5)
2.2.3 Arterially Perfused Wedge Preparations
The isolated wedge preparation was in-
troduced by Yan et al.[72,188] Arterially perfused
slabs of canine and rabbit myocardium are most
frequently used in the model, which is suitable for
recording endo-, midmyo- and epicardial APs
simultaneously.[139] Midmyocardial cell (M cell)
APDs are believed to be important determinants
of QT intervals and TdP arrhythmogenesis,[139]
although their precise role remains somewhat
controversial.[189] For instance, Voss et al.[190] did
not observe a midmyocardial zenith, either in vivo
or in the wedge preparation, under physiological
conditions, raising questions about the functional
role of M cells. The Tpeak-Tend index (interval
between peak and end of the T wave), which re-
flects TDR,[39,72] may provide predictive in-
formation about TDP risk, and the pseudo-ECG
shows proarrhythmic activity.[41] However, Op-
thof et al.[191] found that the Tpeak-Tend does not
correlate with TDR in dogs in vivo, rather corre-
lating with whole-heart repolarization. These
findings question the application of aspects of
wedge data to the in situ heart. Some drugs show
qualitatively different effects on TDR at different
concentrations (e.g. bell-shaped concentration-
response), emphasizing the importance of assess-
ing a wide range of concentrations.[65,157,192,193]
Wedge preparations can also suggest multi-
channel inhibition effects. For example, INa- and
ICaL-blocking actions may be reflected by reduced
contractile force and DTpeak-Tend/QT ratios (ratios
<10 accompanied by QRS widening suggest
combined block of IKr and INa).
[139] Wedge pre-
parations may also be useful in assessing proar-
rhythmic manifestations other than TdP, such as
SQTS-related VT/VF risk as seen with pinacidil
and PD-118057,[194,195] and proarrhythmic con-
sequences of INa and ICaL blockade.
[139,196,197]
A scoring index was recently developed to as-
sess proarrhythmic risk by considering percen-
tage change in QT interval, percentage change in
DTpeak-Tend/QT ratio, and the incidence of EADs
with or without R-on-T extrasystoles and
TdP.[65,139,198,199] Although the ventricular wedge
preparation model has been validated, it has
low throughput and requires complex technical
skills.[63] Recent papers have reported high suc-
cess rates.[139,200]
2.2.4 Langendorff-Perfused Rabbit Hearts
The retrogradely perfused Langendorff AV-
ablated rabbit heart model is one of the most
frequently used preclinical testing methods.
Many drugs have been tested in the fully auto-
mated SCREENIT system introduced by
Hondeghem et al.[45] Epi- and endocardial
monophasic APs (MAPs) are recorded and
proarrhythmic potential characterized by indexes
such as EADs, VT/VF[201] and TRIaD.[25] The
TRIaD concept was introduced by Hondeghem
et al.,[25,45] and stands for: AP Triangulation
(prolongation of APD30-90), Reverse use de-
pendence, AP Instability andDispersion. The use
of TRIaD in SCREENIT correctly identified
proarrhythmic agents of various mechanisms,
even those having small margins between the
hERG IC50 and predicted maximum effective
free therapeutic plasma concentration.[62,202]
TRIaD also predicted proarrhythmic propensity
of 26 drug candidates in a recently published
isolated guinea pig proarrhythmia model.[203]
Although SCREENIT accurately discriminates
proarrhythmic from non-proarrhythmic drugs,
proarrhythmic drug concentrations are some-
times inconsistent.[201,202,204] Lawrence et al.[62]
found that SCREENIT can predict clinical
outcome, particularly for drugs with very high or
very low torsadogenic potential. However, two
or three false-negative results were found in a
study of TdP liability for 55 compounds.[167]
SCREENIT can be useful for testing drugs at
concentrations similar to IC50 values from hERG
assays before committing to more costly in vivo
QTc experiments (e.g. ECG telemetry in dogs and
monkeys).[205] The relationship between TRIaD-
risk drug concentrations and clinical concentra-
tions is likely to be an important index, since
many drugs can produce at-risk TRIaD indexes
at high enough concentrations.[206]
A variety of other isolated heart models in-
volving AV block and different perfusion buffers
have been used to assess TdP liability.[35,207-210]
Pacing sites need to be chosen with caution to
avoid pacing-induced arrhythmias.[211,212] In
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hearts with intact AV conduction, susceptibility
to drug-induced arrhythmia is reduced, owing to
more regular and higher heart rates.[110] Thus,
larger concentrations of drugs are needed to
evoke proarrhythmia compared with AV-
blocked hearts and predictive value is reduced.
Dynamic ECG parameters such as beat-to-beat
variability of ventricular repolarization (BVR) of
QT intervals (short-term variability [STV]; total
instability) were suggested to determine proar-
rhythmic outcome in an in vivo dog proarrhythmia
model.[46,83] In one study, dofetilide increased all
QT variability parameters (an example of typical
dofetilide effects is shown in figure 2); however,
neither verapamil nor lidocaine decrease QT vari-
ability parameters, while both prevent TdP in
isolated rabbit hearts.[35] Most TdP events are pre-
ceded by simple arrhythmias (i.e. VPBs, salvoes of
ventricular beats, bigeminy, etc.), which increase in
number and produce large beat-to-beat irregularity
and instability before TdP. Instability may remain
latent until the appearance of VPBs.[47] Since TdP
is preceded by simple arrhythmias and associated
increased cycle length variation, the use of dynamic
ECG BVR in preclinical studies merits further as-
sessment as a predictive quantitative index.
The most complex in vitro models are the
Langendorff perfused heart models with moder-
ate throughput and high success rate.[63] The
SCREENIT model is a well studied, reproduci-
ble, robust and validated preclinical model with
high sensitivity and specificity that provides
many parameters relevant to proarrhythmia
testing.[62,201,202,204,205] However, all in vitro
models lack crucial elements seen in vivo, such as
metabolite effects and neurohormonal influences.
Furthermore, all models in normal hearts may
fail to inform about TdP risks specific to diseased
hearts, in which proarrhythmia more commonly
occurs. SCREENIT requires a commercial li-
cense, which limits its widespread use. Modified,
manual-method Langendorff models are license-
free and easily available, but less well validated.
2.3 In Vivo TdP Models
In vivo proarrhythmia models are more com-
plex than in vitro models, but provide a wide
variety of information about drug pharmaco-
dynamics and pharmacokinetics. They are
particularly suitable for assessing drugs already
suspected of proarrhythmic risk based on in vitro
studies. In the absence of valid, highly sensitive
and specific surrogate parameters, ICH 7SB re-











































Instability STV LTV RMSSD SD SDSD
Before dofetilide (n = 8)
After dofetilide (n = 8)
QT interval n-1 (ms)
Fig. 2. Beat-to-beat QT variability parameters in isolated atrioven-
tricular-ablated rabbit hearts exposed to dofetilide. (a) Beat-to-beat
QT variability parameters before and after dofetilide administration.
(b) A representative Poincaré plot of an experiment before and after
dofetilide administration, showing the relationship of successive QT
intervals to each other. Under control conditions, values are clus-
tered together, showing little variation. After dofetilide, there is
substantially increased variability, with many data points indicating
alternating long and short QT sequences typifying QT alternans.
LTV = long-term variability; RMSSD = root mean square of succes-
sive QT differences; SD = standard deviation of QT intervals;
SDSD = standard deviation of successive QT differences; STV =
short-term variability. * p< 0.05.
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rabbit model of acquired LQTS developed by
Carlsson et al.[143] is one of the most commonly
used animal models for in vivo QT prolonga-
tion/proarrhythmia screening. In this model, the
TdP liability of a test agent is evaluated during
co-administration of a ‘priming’ substance – the
selective a1-adrenoceptor agonist methox-
amine[143] or phenylephrine.[213-215]
The role of the a1-stimulation in this model is
still unclear. a1-Agonists may affect potassium
currents: methoxamine inhibits transient outward
potassium current (Ito) and prolongs APD in rat
ventricular and rabbit atrial cells (100mmol/L), in-
hibits IK and prolongs APD in canine Purkinje
fibres (0.1–10mmol/L) and inhibits inward rectifier
potassium current (IK1) in canine Purkinje fibres
and rabbit ventricular cells (0.01–1mmol/L).[216-219]
a1-Adrenoceptor stimulation increases intracellu-
lar Ca2+ concentration ([Ca2+]i) via the Gi-IP3/
DAG-PKC pathway (where IP3 is inositol 1,4,5
triphosphate, DAG is diacyclglycerol and PKC is
protein kinase C).[220] Increased [Ca2+]i can lead to
triggered activity and TdP.[15] A role of [Ca2+]i
is supported by the response to nisoldipine (ICaL
inhibitor) and flunarazine (a [Ca2+]i overload
blocker), which dose-dependently prevent TdP
without attenuating the QT prolongation induced
by almokalant, an IKr blocker.
[221] Increased
afterload due to a-adrenergic stimulation may also
increase ventricular stretch. However, neither
stretch nor a1-adrenoceptor stimulation, nor their
combination, enhance dofetilide-induced TdP in
isolated rabbit hearts, suggesting that extracardiac
a1-adrenoceptor-linked mechanisms may play an
important role.[110] Reflex bradycardia could be
involved.[15] However, Wang et al.[222] found that
prazosin pretreatment prevented hypertensive
and bradycardic effects of phenylephrine, but did
not prevent TdP induction by a late INa activator.
The autonomic nervous system per se plays a
significant role in arrhythmogenesis.[101] Sympa-
thetic stimulation increases TDR in LQT1-2.[105]
Bilateral vagotomy prevents clofilium-induced
TdP, suggesting an important contribution of
parasympathetic tone.[111] Baroreceptor sensitiv-
ity (BRS), an indicator of parasympathetic ner-
vous system function, is increased in animals that
develop dofetilide-induced TdP (unpublished
data).
QT measurement in the in vivo rabbit can be
difficult because of very short diastolic periods;
therefore, extrapolation techniques are often
used.[223] Carlsson et al.[79] found recently that STV
predicts TdP in methoxamine-sensitized anaes-
thetized rabbits. However, other investigators have
reported that neither QTc, QT BVR nor AP
triangulation adequately predict TdP.[86,111]
Similarly, Michael et al.[106,119] found that STV
fails to predict TdP in phenylephrine-sensitized or
adrenaline-sensitized anaesthetized guinea pigs. This
model successfully identifies the proarrhythmia
liability of numerous antiarrhythmic drugs,[15] but
is insensitive to quinidine[224,225] and terfena-
dine.[225] Since this proarrhythmia model requires
the sensitizing effect of a1-adrenoceptor stimula-
tion, the proarrhythmic potential of IKr-blocking
drugs with ancillary a1-adrenoceptor blocking
actions (i.e. quinidine, cisapride, etc.) may be un-
derestimated.[15] Additionally, the incidence of
proarrhythmia depends on the anaesthetics
used.[86] These results urge caution in assessing the
proarrhythmia liability of a test drug during
a1-sensitization. Overall, this is a relatively simple,
reproducible, moderate throughput model with a
high success rate that is a useful complement to
other proarrhythmia models, but is not a useful
primary screen.
Conscious ECG Telemetry in Dogs and Monkeys
Technical development has made it possible
to obtain long-term ECG recordings on con-
scious animals. Conscious guinea pig, dog and
monkey ECG telemetry models have been devel-
oped.[145,146,226-228] Beagle dogs and rhesus mon-
keys exhibit low inherent intra-animal variability
and high sensitivity, allowing for the detection of
small but potentially significant increases in
QT/QTc intervals in the range of therapeutic
plasma concentrations.[227,228] Recently, in vivo
QT assays in conscious cynomolgus monkeys
have also been used to assess the risk of
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drug-induced QT interval prolongation.[146]
Champeroux et al.[91] reported that the simple
QT/RR relationship method determined by ECG
telemetry provided a direct assessment of a drug-
induced effect on QT interval, without any curve
fitting or application of correction formulae in
conscious beagle dogs and cynomolgus monkeys.
These models are reproducible and useful to
evaluate in vivo QT prolongation, but usually
they are considered less sensitive for TdP risk due
to the absence of risk factors per se. The sensi-
tivity for QT prolongation can be increased by a
subject-specific QT correction factor.[228]
Slow Delayed-Rectifier Potassium Current-Inhibited
Anaesthetized Rabbit and Canine Models
Lengyel et al.[80] found that neither IKr nor IKs
blockade increase the ECG beat-to-beat QT
STV, and cause TdP with a low incidence, but
STV and the incidence of TdP increase with a
combination of IKr and IKs blockers. Decreased
repolarization reserve with an IKs blocker renders
animals more susceptible to TdP, which may be
useful for drug testing.
Acquired LQT1 with TdP occurs following the
administration of isoproterenol in IKs-inhibited
anaesthetized beagle dogs.[29] Anaesthesia can
interfere with acquired LQTS development, but
the fentanyl-etomidate combination provides
comparable baseline values with conscious tele-
metered beagle dogs,[94] making it useful for
routine cardiovascular safety studies as well as
the investigation of risk biomarkers.[83,229] The
use of IKs-blockade to mimic the reduced re-
polarization reserve commonly predisposing to
TdP in humans is an interesting approach to
obtaining clinically relevant TdP risk data, but
more experience and precise validation of this
method are needed.
2.3.2 Pathological In Vivo TdP Models
An increasing number of experimental models
have been established with electrical (APD pro-
longation associated with decreased outward
repolarizing currents) and structural (ventricular
dilation, hypertrophy, fibrosis) remodelling, mi-
micking the clinical circumstances under which
TdP most commonly occurs. For example, elec-
trical remodelling of the failing myocardium
causes downregulation of IKr, IKs, Ito
[12,230-232]
and ICaL
[233] and upregulation of NCX cur-
rent,[12] and heart failure is a risk factor for TdP.
A decrease in repolarization reserve[155,234] and
abnormal Ca2+ handling[235] predispose such
animals to drug-induced TdP.[12,236-238]
Chronic Atrioventricular-Block Animal Models
The chronic AV block (CAVB) dog TdP
model was established more than a decade
ago.[144] Since then, it has become one of the most
frequently used in vivo TdP screening models,
probably second only to the a1-adrenergic-
stimulated rabbit TdP model.
The bradycardia caused by AV block leads to
volume overload, resulting in increased ventricular
wall strain and diastolic stress.[239-241] The serum
levels of several stress-sensitive hormones increase,
including noradrenaline (norepinephrine), angio-
tensin II, and atrial and brain natriuretic pep-
tides.[12] Haemodynamic and electrical remodelling
develop rapidly and are followed by slower struc-
tural remodelling, with left ventricular hyper-
trophy evolving over 4–6 weeks.[12,60] Remodelling
lengthens APD and promotes triggered activity.
Interestingly, hypertrophy does not appear to be a
prerequisite for electrical remodelling or drug-
induced TdP in this model.[242]
Increased resting [Ca2+]i and spontaneous
sarcoplasmic Ca2+ release occur in CAVB cardio-
myocytes[243] and are likely to play a role in trig-
gered arrhythmias. Transient inward current (Iti;
carried mainly by enhanced NCX activity) can
generate delayed afterdepolarizations.[235]
In the canine CAVB model, the incidence of
arrhythmias is lower in conscious than in anaes-
thetized animals. Vos and colleagues,[12] who
developed the model, generally use a combina-
tion of pentobarbitone (pentobarbital) and ha-
lothane or isoflurane. These agents are known to
have direct electrophysiological actions, blocking
K+-currents and decreasing repolarization re-
serve, bringing the predisposed CAVB phenotype
closer to the proarrhythmic threshold.[244-246]
TdP is produced in >70% of CAVB dogs upon
exposure to IKr blockers associated with drug-
induced LQTS, such as dofetilide, azimilide and
almokalant.[12] Following validation with both
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proarrhythmic and non-proarrhythmic drugs,
the CAVB dog model is now considered suitably
reproducible and sensitive for new-drug evalua-
tion.[12,60] However, only 65–70% of CAVB dogs
are drug-susceptible and can be used for testing,
which is a nontrivial limitation.[12]
Tsuji et al.[232] reported that CAVB, brady-
paced rabbits are at high risk of spontaneous TdP.
CAVB/bradypacing causes remodelling of ion-
channel function, particularly IKs and IKr down-
regulation. Tachypaced rabbits also develop
heart failure and ionic-current remodelling, with
downregulation of IKs but not IKr, and show
isolated ventricular ectopy but not TdP.[232]
However, dofetilide administration reveals im-
paired repolarization reserve and induces TdP in
tachypaced rabbits. The tachypaced CAVB rab-
bit model may thus be suitable for proarrhythmia
testing, since spontaneous TdP does not occur,
and decreased repolarization reserve produces a
high likelihood of TdP with IKr blockade. In ad-
dition to K+-channel downregulation and APD
prolongation, Ca2+-handling abnormalities caus-
ing increased cell Ca2+ loading and Ca2+-calmo-
dulin-dependent protein kinase II activation ap-
pear to play an important role in EAD generation
and arrhythmogenesis in this model.[247]
Recently, a CAVB monkey model was in-
troduced by Satoh et al.[248] This system may
have significant advantages over previous TdP
models, both because of the phylogenetic simi-
larity to humans and because TdP almost always
terminates spontaneously, limiting collateral
mortality. The low mortality rate allows for the
comparison of multiple drugs in individual ani-
mals; furthermore, experiments with monkeys
require smaller amounts of drugs, because of
their small size[249] and specific properties of me-
tabolism by cytochrome P450 (CYP) 3A4.[250]
The CAVB models have low throughput
compared with other preclinical assays, demand
high technical skills and require further valida-
tion before more widespread use in proar-
rhythmia safety studies.
Failing Rabbit Hearts
Kijtawornrat and colleagues[36,251] introduced
a TdP model in rabbits with myocardial infarc-
tion-induced heart failure. Heart failure rabbits
developed TdP in greater number than normal
rabbits after the administration of dofetilide,
clofilium and cisapride. Increased temporal dis-
persion and abnormal Ca2+ cycling were thought
to contribute to the TdP predisposition.[36,251]
Cardiomyocytes from the ischaemic area showed
increased Ca2+ spark frequency related to spon-
taneous Ca2+ release from the sarcoplasmic re-
ticulum: Ca2+-release events can cause triggered
activity that initiates TdP.[36,251] This model re-
quires further validation before wider use for
proarrhythmia screening.
3. Clinical Proarrhythmia Analysis
3.1 Clinical LQTS Biomarkers
The next step after preclinical risk assessment
is evaluation of clinical proarrhythmic potential.
The development of TdP is often preceded by
alternation in T-wave morphology, i.e. T-wave
alternans (TWA).[67-69,252-254] In a TdP predictor
identification study in humans, TWA was found
to be more common in patients with TdP.[255,256]
Shimizu and Antzelevitch[257] suggested that
TWA at rapid rates under LQT conditions results
from alternation in M-cell APD, leading to ex-
aggeration of TDR. TWA also occurs in LQTS at
relatively slower heart rates, at which TWA may
be less likely.[70] Shah and Hondeghem[25] argued
that AP instability is the experimental counter-
part of TWA. Thus, TWA may provide in-
formation about increases in both the temporal
and spatial dispersion of repolarization. The
digital signal-processing counterpart of TWA,
microvolt-level TWA, may detect subtle degrees
of TWA and is also a broader marker of ven-
tricular tachyarrhythmia vulnerability.[70] How-
ever, Schmitt et al.[258] found that in patients with
congenital LQTS with a history of life-threaten-
ing arrhythmias but free of structural heart dis-
ease, microvolt-level TWA assessment does not
provide additional prognostic information.
After STV was found to predict TdP in some
experimental models, increased STV in QT pa-
rameters was observed in patients with both
drug-induced and congenital LQTS.[81,82] Berger
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et al.[89] developed a QT variability index based
on aggregate deviations over a defined time win-
dow from a template QT interval, corrected for
heart rate. The QT variability index is increased
in patients with dilated cardiomyopathy, hyper-
trophic cardiomyopathy and cardiac electrical
disease,[259] as well as in patients with congenital
LQT1 and LQT2.[90]
Schwartz et al.[96] found that low BRS is a
protective factor in LQT1 patients, possibly be-
cause lower baroreflex responsiveness prevents
arrhythmogenic cycle-length swings. In addition,
beat-to-beat QT variability is affected by drugs
that modulate the autonomic nervous system.[260]
Heart rate turbulence (HRT) is a non-invasive
index of autonomic function based on the re-
lationship between initial acceleration and sub-
sequent deceleration of sinus rhythm following a
ventricular ectopic beat.[98] HRT is predictive
of tachyarrhythmia occurrence in patients with
implanted defibrillators.[261,262] The data are
presently insufficient to judge the potential
predictive value of HRT for TdP.
Despite the range of potential proarrhythmia
biomarkers used at the preclinical level, at present
the QTc interval remains the only proarrhythmia
biomarker in widespread clinical use. However,
QTc interval prolongation has significant limita-
tions as a biomarker:[25,263] (i) there are drugs (e.g.
ranolazine[164]) that lengthen QTc without causing
TdP, and some QT-lengthening drugs (e.g. amio-
darone, verapamil[163]) can prevent TdP, limiting
the specificity of QTc prolongation; and (ii) TdP
can develop without QT prolongation in isolated
rabbit hearts (with droperidol, haloperidol, terfe-
nadine),[45,202,204] and in humans,[264] limiting the
sensitivity of QTc prolongation.
Bazett’s square-root correction is the most
common formula used to calculate heart rate
QTc in clinical practice[265] and is the formula
implemented in most commercial ECG ma-
chines.[266,267] However, the Bazett formula over-
corrects at high heart rates and under-corrects at
low heart rates, and can be particularly proble-
matic outside the 60–100 beats/min ‘normal’ HR
range.[268] In humans the dynamic QT/RR re-
lationship exhibits large intersubject and lower
intrasubject variability.[269] Circadian QTc inter-
val variability is also a factor.[270] Thus, ideally,
the individual drug-free QT/RR relationship
should be considered when assessing the post-
drug relationship.[269,271] Several proarrhythmic
drugs steepen the QT/RR slope (reflecting re-
verse-use dependence), so that the repolarization-
heart rate relationship itself may be useful for
LQTS proarrhythmia risk assessment.
3.2 ‘Thorough QT Study’
The ICH E14 clinical assessment guidance
document[20] suggests the performance of a hu-
man ‘thorough QT study’ (TQTS) according to a
detailed protocol summarized in table V. The
timing of the TQTS is not defined in the gui-
dance, but conducting the TQTS in early drug
development can avoid additional expenses if
Table V. Thorough QT study: main points
Objective QT/QTc interval effect of the new agents
Cardiovascular adverse effects
Timing As early as feasible (even during clinical
phase I)
Subject enrolment Healthy volunteers
Design Placebo control group
Randomized
Appropriately blinded
Positive control group (validate assay
sensitivity)
Group design:
crossover (smaller number of patients
required because of reduced intersubject
variability)
parallel
Dose effect Dose-response relations
Concentration-response relationships (even
at high concentrations, ‘worst case scenario’)





Multiple time points including peak
concentration (Cmax)
Protocol specified QT evaluationa and
correction to heart rate (i.e. Bazett or
Fridericia)
a Authors’ suggestion: ECG should be evaluated in a randomized
and blinded fashion in only the samepre-specified lead(s) using the
same semiautomatic or manual QT interval measurement method.
QTc= corrected QT interval.
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substantial risk is detected. Shah[272] suggested
that a well designed ECG monitoring and QT
concentration assessment as part of phase I clin-
ical assessment may preclude a later TQTS;
however, this idea remains to be considered by
regulatory authorities.
The TQTS is considered negative when the
upper bound of the 95% one-sided confidence
interval for the time-matched effect of the drug
onQTc excludes a 10ms prolongation. Expanded
ECG safety assessment may also be necessary in
certain patient subgroups during later stages of
drug development.[272] Jonker et al.[273] found in
a pharmacokinetic-pharmacodynamic (PK/PD)
model that 10% inhibition of hERG currents by
dofetilide corresponds to 20ms of QT interval
prolongation in humans (95% CI). This suggests
that PK/PD modelling may predict the human
QT response and provide useful information for
integrated QT risk assessment.
Besides determining QT/QTc-prolonging po-
tential of a test drug, the rate of arrhythmia (TdP,
VT, VF) and adverse events (syncope, seizure,
SCD) should be compared between treated and
control patients. Because of the large sample sizes
needed to detect rare but clinically significant
arrhythmic events, postmarketing surveillance is
important. Substantial QT/QTc interval pro-
longation during clinical development can be the
basis for non-approval or discontinuation of an
otherwise promising compound, even without
proarrhythmia per se. Decisions about continua-
tion of development and approval generally
depend on the estimated proarrhythmic risk, the
likely therapeutic benefit and the safety/efficacy
of alternative therapies.
TQTS is quite sensitive for QT-prolonging
proarrhythmic drugs, but its specificity is ques-
tionable. Verapamil, amiodarone and ranolazine
are all examples of compounds that prolong the
QT, but have little or no clinical proarrhythmic
risk.[274]
4. Detecting and Preventing
Proarrhythmia in Clinical Practice
Drug-induced TdP is relatively rare, but it is
hard to estimate the occurrence rate precisely.
Many cases are not reported, definitive diagnosis
requires ECG recording and other conditions can
also lead to SCD (e.g. heart failure, cardiomyo-
pathy). In addition, relative clinical TdP risk is
difficult to quantify precisely for various drugs,
because the intrinsic risk of the target population
can differ greatly. For example, a drug given to
patients with significant risk of cardiac damage
and dysfunction, such as an antiarrhythmic, may
for that reason alone be observed to cause TdP
much more frequently than a drug commonly
given to patients without heart disease, such as a
macrolide antibacterial. Clinicians are ultimately
responsible for the safety of the patients to whom
they prescribe drugs, for proarrhythmia as well as
other safety concerns.[275] A silent gene mutation
affecting cardiac repolarization has been detected
in 10–40% of patients with acquired LQTS.[276,277]
Individuals who carry such asymptomatic muta-
tions are at increased risk for TdP development
when a potentially proarrhythmic drug is ad-
ministered. The recognition of at-risk individuals
is an important challenge. Future personalized
medicine/genomic technologies may greatly fa-
cilitate recognition of patients with gene-variants
predisposing them to TdP risk. In the meantime,
awareness of the risk associated with potential
QT-prolonging drugs and ECG verification after
initiation of therapy are crucial.
Thus, clinicians must be aware of the dose-
related proarrhythmic potential of various agents
and of proarrhythmia risk factors (table VI).
Female gender, structural heart disease, advanced
age and coadministration of other potential QT-
prolonging agents are important risk factors.[314]
Even non-prescription drugs (e.g. antitussive
agents) can increase TdP risk for patients taking
other pharmaceutical preparations or having
concomitant disease; therefore, caution is needed
with unsupervised use of non-prescription med-
ication.[303] In addition, food and beverages may
contain potentially proarrhythmic chemicals.
Grapefruit juice containing naringenin inhibits
the metabolism of several drugs such as the class
III antiarrhythmics sotalol and amiodarone.[304]
The consumption of large amounts of grapefruit
juice or tonic water containing quinine (optical
isomer of quinidine) can be deadly in predisposed
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patients, such as those with congenital LQTS
channelopathies.[315]
Potential drug interactions via inhibition of
CYP isoenzymes were responsible for 24% of
cases in a recent study of patients with acquired
LQTS.[271] Metabolic interactions can greatly in-
crease the risk of TdP with commonly used drugs.
For example, an increasing number of deaths and
life-threatening events have been reported in res-
ponse to methadone coadministered with various
drugs. Wilcock and Beattie[316] concluded that a
major contributing factor is a lack of knowledge
among clinicians about the need to carefully in-
itiate and monitor the use of methadone because
of its wide interindividual variation in pharm-
acokinetics. Terfenadine, an antihistamine that
was withdrawn from the market, is metabolized
by CYP3A4 and normally causes slight (mean
~6ms) QT prolongation in humans. However, a
study using in vitro microsomal preparations
from human livers showed that coadministra-
tion with the antifungal agent ketoconazole
(which inhibits CYP3A4) would be expected
to increase terfenadine blood concentrations by
13- to 59-fold.[317] Such high concentrations of
terfenadine can cause marked QT prolongation
and susceptibility to TdP.[318] Mutations in genes
encoding metabolizing enzymes (i.e. CYP2D6,
CYP3A4) can substantially increase the serum
concentrations of proarrhythmic drugs. The
blood levels of the torsadogenic antipsychotic
Table VI. Clinical risk factors for drug induced long-QT (LQT)
syndrome
Risk factors References
Age >65 years 278
Female gender 279
Cardiovascular diseases 278




arrhythmogenic right ventricular dysplasia 284
Takotsubo cardiomyopathy 285
ischaemic heart disease 283
recent myocardial infarction 283
heart failure (NYHA III, VI) 283
arrhythmias
recently converted atrial fibrillation conduction 286,287












Autonomous nervous system lability 101
increased sympathetic tone
Family history
family members with definite LQT1 296




















foods, drinks, liquid protein diet 306-309







CYP = cytochrome P450; NYHA =New York Heart Association heart
failure classification; SCD = sudden cardiac death; VPB = ventricular
premature beat; VT = ventricular tachycardia.
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drug thioridazine and its metabolites increase
and QT interval lengthens in patients with ab-
normal drug metabolism.[319] Considering the
many genetic variants in repolarization channel
gene sequences and metabolizing enzymes that
can predispose to TdP, and the increasing num-
ber of potential QT-prolonging drugs, efficient
personalized medicine approaches to the preven-
tion of TdP remain a major challenge.
Given the difficulties in avoiding exposure of
patients to potential QT-prolonging interven-
tions, efficient detection is important. ECG re-
cordings should be obtained in patients treated
with drugs that can cause LQTS if there is any
concern for potential LQTS, and particularly if
they have risk factors for LQTS or suspicious
clinical symptoms such as palpitations, light-
headedness or syncope. A QTc >500ms sub-
stantially increases TdP risk in patients with
congenital LQTS.[320] In one study of acquired
LQTS, the majority of TdP cases occurred at
QTc >500ms.[321] In the DIAMOND (Danish
Investigations of Arrhythmia and Mortality on
Dofetilide) study, female gender, the severity of
heart failure and QTc duration identified patients
at increased risk of early TdP upon dofetilide
exposure.[283] In a large congenital LQTS patient
database, the mean QTc was 482ms and in-
dividual values ranged from 365 to 800ms.[322] A
recent survey showed that practising emergency
room physicians rely heavily on Bazett-corrected
QTc to assess LQTS risk, and that physician
education and improved QT assessment guide-
lines are important for detection and prevention
of acquired LQTS-related tachyarrhythmias.[265]
Males with QTc £330ms and females with QTc
£340ms should be suspected of having congenital
SQTS, even if they are asymptomatic.[323] With
increasing awareness of drug-induced SQTS,
similar criteria may be appropriate, although
there is presently limited knowledge about the
acquired condition.
In addition to ion-channel dysfunction, ab-
normalities in K+-channel trafficking due to
congenital mutations or drug effects can cause
LQTs.[319,324,325] It was recently demonstrated
that some drugs can improve the trafficking of
ion channel proteins. Paradoxically, cisapride
could produce a ‘double hit’ effect on repolariza-
tion by improving the trafficking of gain-of-
function-mutated INa channel (SCN5A) subunits,
leading to QTc lengthening, compounded by the
drug’s blocking effect on IKr. Better understanding
of such complexities may help to better predict and
prevent acquired LQTS in the future.
5. Conclusions
Despite detailed preclinical and clinical pro-
arrhythmia core batteries of safety pharmacol-
ogy, drug proarrhythmia risk assessment remains
imperfect. Thus, even drugs judged to have rela-
tively low proarrhythmia risk may need further
surveillance after marketing. Post-approval clin-
ical trials or surveillance programmes focusing on
a small number of specified potential arrhythmic
outcomes might allow for earlier identification
of proarrhythmic properties, leading to altered
labelling or, where necessary, the withdrawal of a
drug.[324] Despite the great progress that has al-
ready beenmade, further work is needed to validate
various preclinical proarrhythmia models and
develop new, more sensitive, specific and clini-
cally relevant models and proarrhythmia bio-
markers. Newer transgenic models (e.g. rabbit,
zebrafish) may provide helpful complementary
approaches.[325] In the future, more reliable pre-
clinical data, developments in pharmacogenomics
and more advanced detection of genetic disorders
may allow for personalized therapy taking into
account individual patient risk factors for pro-
arrhythmia. In the meantime, clinicians must be
aware of proarrhythmic drugs, proarrhythmia
labelling restrictions and proarrhythmia risk
factors to provide pharmacological treatment
with minimal proarrhythmic risk.
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